Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

Abstract The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the s...

Full description

Bibliographic Details
Main Authors: Mario Tiribelli, Ahmet Emre Eskazan
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-08-01
Series:Oncology and Therapy
Subjects:
Bosutinib
Chronic myeloid leukemia
Dasatinib
Imatinib
Ponatinib
Tyrosine kinase inhibitor
Online Access:http://link.springer.com/article/10.1007/s40487-019-00098-w

Internet

http://link.springer.com/article/10.1007/s40487-019-00098-w

Similar Items